PUBLICATIONS

Cost Effectiveness of Radiation and Chemotherapy for High-Risk Low Grade Glioma
Journal Article

The standard of care treatment for maximally resected, high risk (≥ 40 years old or sub-totally resected) low grade glioma (LGG) patients was established by RTOG 9802, which showed an overall survival (OS) of 13.3 years for patients treated with radiotherapy (RT) + PCV (procarbazine, lomustine [CCNU], vincristine) chemotherapy compared to 7.8 years for RT alone. In the era of value-based health care, cost-effectiveness analyses (CEA) have the potential to inform coverage decisions and patient care. To our knowledge, there has been no study assessing the value of RT+PCV as adjuvant therapy for high risk LGG. We sought to analyze the cost-effectiveness of this strategy.

Publication Materials
Cost Effectiveness of Radiation and Chemotherapy for High-Risk Low Grade Glioma Download

Share This Publication